Choose PT-141 nasal spray for seconds-long administration of a centrally acting desire medication. Rebody offers one 5 mg/mL bremelanotide presentation in a refrigerated 5 mL bottle; the prescription translates concentration and pump output into the exact sprays per use.
The short answer
The bottle contains bremelanotide at 5 mg/mL. That number describes concentration, not the amount delivered in one prescribed use.
The nasal format wins for someone who wants a compact as-needed object without injection or oral dissolve time. Rebody standardized the nasal route on one concentration so the bottle, price, and intake path stay consistent.
Nasal options at a glance
| Product fact | Rebody nasal presentation |
|---|---|
| Active | Bremelanotide |
| Concentration | 5 mg/mL |
| Bottle | 5 mL |
| Storage | Refrigerated |
| Metered output | See dispensing label |
| Sprays per prescribed use | Patient-specific |
The 5 mL bottle is $99.50 first month, then $199. Days of supply, actuation count, and refill cadence remain prescription-specific.
Concentration is not dose
Milligrams per milliliter tells you how much active is present in a volume. The actual dose depends on how many milliliters one actuation dispenses and how many actuations are prescribed.
At 0.1 mL per metered spray, the 5 mg/mL bottle delivers 0.5 mg per spray. The prescribed actuation count determines the dose.
Do not halve or double sprays by mental conversion. Use the written directions for the dispensed bottle.
What the small nasal studies show
A double-blind crossover experiment gave one 20 mg intranasal dose to 18 premenopausal women with female sexual arousal disorder. Researchers evaluated physiological and subjective arousal measures.
Another early program studied intranasal PT-141 in healthy men and men with mild-to-moderate ED, examining pharmacology, tolerability, and erectile response.
These studies establish intranasal bremelanotide as a real human research route in both women and men. Rebody's pump output, prescribed dose, and timing come from the finished product and its label.
How the approved evidence fits this route
Vyleesi is a 1.75 mg subcutaneous bremelanotide injection approved for acquired, generalized HSDD in premenopausal women. Its pivotal 24-week trials measured desire and distress.
The injection label cannot be converted to a nasal dose. Subcutaneous and intranasal routes have different exposure, timing, formulation, and package behavior.
Use Vyleesi to explain bremelanotide's approved population and active-level safety questions. Do not call a compounded nasal spray FDA-approved or clinically equivalent.
Why Rebody offers one nasal concentration
Rebody uses 5 mg/mL as its standard nasal presentation. This concentration supports a 1 mg starting administration with two sprays total and a 2 mg administration with four sprays total.
The useful number is the drug delivered per actuation on the finished label. The clinician and pharmacy translate that number into sprays per prescribed use.
Priming and first use
A metered nasal pump may need priming before first use or after a period without use. The number of presses, whether to spray into air, and when to reprime depend on the exact dispenser.
Use only the priming instructions supplied with this bottle. Overpriming can waste medication and make the bottle run out early.
The dispensing instructions cover cap removal, bottle orientation, nostril placement, inhalation, and cleaning.
Nostril technique and congestion
The approved SIG must state whether sprays alternate nostrils and what to do when more than one actuation is used. Aim and inhalation can change throat runoff and local irritation.
Congestion, a cold, nosebleed, recent nasal procedure, or damaged mucosa can affect comfort and delivery. Do not compensate with extra sprays.
If liquid repeatedly runs down the throat or out of the nose, check technique and dispenser function rather than assuming the dose failed.
Timing and duration
Search results are full of exact onset and multi-hour duration claims. The Rebody bottles do not have route-specific final guidance establishing those numbers.
The approved injection is used at least 45 minutes before anticipated activity, but that is not a nasal instruction. The 20 mg women's nasal experiment and early men's studies used study-specific timing.
Use the prescribed lead time when approved. Do not redose because an internet countdown passed without a felt effect.
Leaking, blocked, or early-empty bottles
Keep the cap on and bottle upright when instructed. A leaking pump, cracked bottle, blocked actuator, irregular mist, or visible damage can change delivered volume.
Do not poke the nozzle with a pin, add liquid, or move medication into another spray bottle. Record the issue and remaining supply.
An early empty bottle may reflect overpriming, leakage, excess sprays, or a mistaken actuation count. Resolve the cause before refill.
Refrigeration and travel
The bottle is refrigerated. Keep the original labeled bottle protected from freezing and direct ice-pack contact. Ask how long the final formula can remain out of refrigeration.
For travel, use a leak-resistant secondary pouch and keep the cap in place. Do not decant. Airline and security questions are easier when the prescription label remains visible.
If a shipment arrives warm, report timing and package condition. Coldness, clarity, or color alone cannot determine stability.
Side effects and urgent symptoms
The Vyleesi label's common and serious questions include nausea, flushing, headache, vomiting, injection-site reactions, transient blood-pressure increase, reduced heart rate, focal hyperpigmentation, and delayed gastric emptying. Injection-site reactions obviously do not describe nasal use.
Nasal route can add local irritation, congestion, unpleasant taste, runoff, or nosebleed questions. Product-specific rates are not established for these bottles.
Uncontrolled hypertension and known cardiovascular disease are contraindications on the approved injection label. Seek urgent care for chest pain, fainting, severe allergic symptoms, concerning blood-pressure symptoms, or prolonged painful erection.
Interactions and maximum use
The Vyleesi label warns that delayed gastric emptying can affect oral medication absorption and that bremelanotide can reduce systemic exposure to oral naltrexone. These are active-level questions that deserve attention.
The injection limit of one dose in 24 hours and eight doses per month is not a nasal-spray instruction. Use the frequency printed on the nasal prescription.
Alcohol, sildenafil, tadalafil, antihypertensives, and other sexual-health treatments require product-specific guidance rather than a public stack recipe.
Price, doses per bottle, and refills
The PT-141 nasal spray is $99.50 first month, then $199 per 5 mL bottle. A 5 mL bottle cannot be priced per dose until metered volume, prescribed sprays, priming waste, actuation count, and billable days of supply are known.
Before starting, confirm concentration, amount per spray, expected prescribed uses per bottle, storage, package price, and refill timing. Those facts change the purchase.
The customer price is $99.50 first month, then $199 per bottle. The bottle is not automatically a one-month supply because prescribed use varies.
Questions people ask
Does 5 mg/mL tell me the dose?
No. It tells you the concentration. The delivered dose still depends on pump output and prescribed sprays.
How many sprays should be used?
Use the number printed on the prescription label. Concentration and bottle volume alone are not enough to answer.
What did nasal PT-141 research measure in women?
A double-blind crossover experiment gave one 20 mg intranasal dose to 18 premenopausal women and measured physiological and subjective arousal. It provides a direct human nasal research lane while the Rebody bottles retain their own dose and instructions.
What did nasal PT-141 research measure in men?
Early controlled intranasal studies in healthy men and men with mild-to-moderate ED measured pharmacology, tolerability, and erectile response, supporting continued interest in centrally acting bremelanotide for male sexual health.
Can the bottle travel unrefrigerated?
Use the final temperature and excursion instructions. Do not assume a universal time.
Bottom line
PT-141 nasal spray is the quickest physical route in Rebody's bremelanotide family: a compact, refrigerated 5 mg/mL bottle that turns a centrally acting desire medication into a seconds-long step. It is $99.50 first month, then $199 per 5 mL bottle; the prescription label supplies the metered-dose directions.
Keep exploring PT-141
- Compare every needle-free PT-141 format
- See PT-141 mini troche strengths
- Read PT-141 nasal spray vs troche
- See the PT-141 nasal spray product
Primary sources
- FDA. Vyleesi prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf
- Diamond LE, Earle DC, Rosen RC, et al. Intranasal crossover experiment in 18 premenopausal women. https://pubmed.ncbi.nlm.nih.gov/16839319/
- Rosen RC and colleagues. Intranasal PT-141 in healthy men and men with mild-to-moderate ED. https://pubmed.ncbi.nlm.nih.gov/14963471/